Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

A group of researchers from the University of Erlangen-Nuremberg has discovered which immune cells migrate from the skin of ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

In a phase IIIb trial of adults with active psoriatic arthritis (PsA) and obesity or overweight, adding the GLP-1 drug ...

Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...

On Jan. 1, 2026, the price of my medication finally came down — and it will change my life. I have been living with psoriatic arthritis for over 40 years, a condition that I treat with a medication ...